Arcturus Therapeutics (ARCT) Tops Q3 EPS by $1.01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress
November 14, 2023 4:01 PM ESTExpected cash runway extended to the end of 2026
$35 million milestone achieved under CSL collaboration
ARCT-154 remains on track for Japan-NDA approval in December
Enrollment target reached in Phase 3 bivalent COVID vaccine comparison trial
Enrollment initiated in ARCT-032 Phase 1b study; dosing first cystic fibrosis patient this month
ARCT-032 received Rare Pediatric Disease Designation for cystic fibrosis from the FDA
Investor conference call at 4:30 p.m. ET November 14, 2023
SAN DIEGO--(BUSINESS WIRE)-- Arcturus... More
